Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer

Mol Genet Metab. 2000 Sep-Oct;71(1-2):315-20. doi: 10.1006/mgme.2000.3044.

Abstract

The insulin-like growth factor-I receptor (IGF-I-R) has a central role in normal cellular proliferation as well as in transformation processes. Transcription of the IGF-I receptor gene is controlled by a number of tumor suppressors, including WT1, p53, and BRCA1. It has been demonstrated that, in their wild-type form, these transcription factors can suppress the activity of the IGF-I-R promoter, with ensuing reduction in the levels of cell-surface IGF binding. On the other hand, a number of oncogenes, including mutant p53 and c-myb, and the fusion protein EWS-WT1 significantly stimulate promoter activity. Interactions between stimulatory and inhibitory transcription factors may determine the level of expression of the IGF-I-R gene and, consequently, the proliferative status of the cell.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Apoptosis
  • Cell Cycle
  • Gene Expression Regulation
  • Genes, Tumor Suppressor*
  • Humans
  • Neoplasms / etiology
  • Neoplasms / genetics*
  • Neoplasms / prevention & control
  • Oncogenes*
  • Receptor, IGF Type 1 / genetics*
  • Somatomedins / metabolism

Substances

  • Somatomedins
  • Receptor, IGF Type 1